Brigatinib

Overview

Brigatinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL3545311).

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Brigatinib expires 10 Nov 2035 and exclusivity 22 May 2027. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine

Canonical SMILES

CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC

InChIKey

AILRADAXUVEEIR-UHFFFAOYSA-N